View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Martin Huseby Karlsen
  • Martin Huseby Karlsen

Valuation and market update

In this note, we show updated valuation and market statistics for the Offshore Drilling sector.

Rune Majlund Dahl
  • Rune Majlund Dahl

Genmab (Buy, TP: DKK2630.00) - Epinkly off to a good start in 2024

Q1 sales beat our forecast and consensus due to higher product-related royalties and solid Epkinly sales, while the operating profit margin was softer than expected owing to higher opex. Genmab reiterated the 2024 guidance for sales of DKK18.7bn–20.5bn, opex of DKK12.4bn–13.4bn, and operating profit of DKK4.6bn–7.1bn. We expect a strong pipeline of news flow in 2024. We reiterate our BUY and DKK2,630 target price.

Martin Huseby Karlsen
  • Martin Huseby Karlsen

Consensus back in focus and tier-2 deepwater risk

With the start of the Q1 reporting season for Offshore Drilling, we sense increased investor attention on the risk to consensus. Although we like the investment case for its valuation in the out-years (2026), our estimates remain below consensus. We see potential for share price volatility as near-term consensus is revised lower, while investors gradually underwrite 2026 valuations. We also believe the gaps between contracts and increased idle-time risk for tier-2 deepwater rigs are not properly...

 PRESS RELEASE

Genmab Announces Financial Results for the First Quarter of 2024

Genmab Announces Financial Results for the First Quarter of 2024 May 2, 2024 Copenhagen, Denmark; Interim Report for the First Quarter Ended March 31, 2024 Highlights The U.S. Food and Drug Administration (U.S. FDA) granted Priority Review for the supplemental Biologics License Application (sBLA) for EPKINLY® (epcoritamab-bysp) for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy, with a Prescription Drug User Fee Act (PDUFA) target action date of June 28, 2024An additional Phase 3 clinical trial was initiated...

Carlsberg AS: 1 director

A director at Carlsberg AS bought 499 shares at 944.575DKK and the significance rating of the trade was 71/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly sh...

 PRESS RELEASE

Transocean Ltd. Announces Consent Solicitation for 8.375% Senior Secur...

Transocean Ltd. Announces Consent Solicitation for 8.375% Senior Secured Notes due 2028 STEINHAUSEN, Switzerland, May 01, 2024 (GLOBE NEWSWIRE) -- Transocean Ltd. (NYSE: RIG) announced today that its wholly owned and indirect subsidiary, Transocean Titan Financing Limited (the “Company” and, together with Transocean Ltd., “Transocean”), is soliciting consents (“Consents” and, such solicitation being referred to herein as, the “Consent Solicitation”) from holders (the “Holders”) of its outstanding 8.375% Senior Secured Notes due 2028 (the “Notes”) as of 5:00 p.m. New York City time, on Apr...

Transocean Inc.: Improved deepwater market and robust backlog provide ...

Our credit view of this issuer reflects its contracted revenue backlog of $8.9 billion, constrained by its high debt levels and complex capital structure.

ABGSC Food & Beverage Research ... (+2)
  • ABGSC Food & Beverage Research
  • Peter Sehested

Guidance looks low and consensus high

2024e forecasts unchanged, '25e-'26e up by 1-2%. Q1 was a good start to a busy year. HOLD, TP of DKK 1,000.

ABGSC Capital Goods Research ... (+2)
  • ABGSC Capital Goods Research
  • Haakon Amundsen

A good start to the year

Q1 EPS 7% above, but some special elements. Backlog implies revenue estimates are robust. Strong momentum, high expectations - HOLD.

Niclas Gehin
  • Niclas Gehin

Kongsberg Gruppen (Hold, TP: NOK780.00) - Solid Maritime margin beat i...

Q1 EBITDA beat our estimate and consensus by 9%, explained by a stronger Maritime (KM) margin than expected. However, as previously guided, the Defence (KD) margin did fall to 17% in this quarter. We have edged our 2025–2026e EPS up 2% after primarily raising our KM margin assumptions, but reiterate our HOLD and NOK780 target price as we believe the stock is already pricing in a possible ramp-up of NATO defence spending to at least 2.5% of GDP for all member states.

Jesper Ingildsen
  • Jesper Ingildsen

Carlsberg (Buy, TP: DKK1110.00) - Solid start to the year

Overall, we consider the Q1 results a solid start to the year, with China’s and the premium beer momentum especially encouraging and supporting our view that the unchanged 2024 guidance looks conservative. We see room for positive earnings momentum throughout the year, with good weather providing upside potential. We thus reiterate our BUY and DKK1,110 target price.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Compass: Weekly Equity Strategy

Are the Lows "In" for this Pullback? While we are not yet out of the woods, we continue to see evidence that suggests the lows may be "in" for this pullback. Last week (4/23/24 Compass) we discussed the possibility that further downside was limited on the S&P 500 due to a multitude of reasons (SPX had simply filled 2/22/24 gap support that we had been discussing since late-February, Russell 2000 and Equal-Weighted S&P 500 were holding above key supports, short-term oversold conditions, subdued ...

ABGSC Food & Beverage Research ... (+2)
  • ABGSC Food & Beverage Research
  • Peter Sehested
 PRESS RELEASE

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat R...

TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer Company Announcement Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK compared to chemotherapyTIVDAK is the first antibody-drug conjugate in this patient population to have positive overall survival data COPENHAGEN, Denmark; April 30, 2024 – (Nasdaq: GMAB) and (NYSE: PFE) announced today the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TIVDAK® (tisotumab vedotin-tftv) f...

 PRESS RELEASE

Transocean Ltd. Reports First Quarter 2024 Results

Transocean Ltd. Reports First Quarter 2024 Results              Three months ended     March 31,  December 31,    Sequential 2024 2023 change(In millions, except per share amounts and backlog)           Contract drilling revenues$763   $741   $22  Adjusted contract drilling revenues$767   $748   $19  Revenue efficiency(1) 92.9 %    97.0 %    (4.1)%  Operating and maintenance expense$523   $569   $(46) Net income (loss) attributable to controlling interest$98   $(104)  $202  Diluted earnings (loss) per share$0.11   $(0.13)  $0.24              Adjusted EBITDA$199   $122   $77  Adjusted EBITDA...

Martin Huseby Karlsen
  • Martin Huseby Karlsen

Transocean Minor model adjustments

We have updated our estimates, primarily due to Transocean’s recent fleet status report. Despite having small delays included in the fleet status report, we remain just above the guidance and largely in line with Bloomberg consensus ahead of the Q1 results (due today after market close). We expect Q1 EBITDA of USD195m, largely in line with consensus (USD190m) and just above the guidance (USD188m). We do not consider these changes to be material, and we have not changed our HOLD recommendation. W...

 PRESS RELEASE

Transactions in Connection with Share Buy-back Program Genmab

Transactions in Connection with Share Buy-back Program Genmab Company Announcement COPENHAGEN, Denmark; April 29, 2024 – Genmab A/S (Nasdaq: GMAB). On March 15, 2024, Genmab announced the initiation of a share buy-back program to repurchase up to DKK 3.5 billion worth of shares. The share buy-back program is expected to be completed no later than December 16, 2024. The following transactions were executed under the program from April 22, 2024 to April 26, 2024:  Trading PlatformNo. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement 408,701 836,159,5...

Niclas Gehin
  • Niclas Gehin

Norsk Hydro (Sell, TP: NOK50.00) - Q1 slightly on the soft side

Q1 EBITDA was c2% below consensus, with a somewhat soft mix, as Extrusions and Aluminium Metal, the two largest segments, were below forecasts. We have increased our 2024e EPS by 7% on the USD2,600/t spot aluminium price, and 2025–2026e by 2% on the Q1 results. We are 30% below consensus 2025e EBITDA; we do not see enough demand to raise aluminium prices above the marginal producer’s cost, as the price appreciation in recent weeks suggests. We still expect aluminium prices to decline with lower ...

ABGSC Metals & Mining Research ... (+3)
  • ABGSC Metals & Mining Research
  • Bengt Jonassen
  • Martin Melbye

Demand growing faster than supply - BUY

Q1'24 EBITDA of NOK 5.4bn, '24e-'26e EBIT up 2-3% post report. Market tightening rapidly in Q1 - demand up 5%, supply up 3%. Reiterate BUY — TP NOK 75.

Martin Huseby Karlsen
  • Martin Huseby Karlsen

Valuation and market update

In this note, we show updated valuation and market statistics for the Offshore Drilling sector.

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch